Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Konkret geht es um den Diabetes-Patienten mit kardiovaskulären Erkrankungen oder Risiken, die Herzinsuffizienz sowie die kardiovaskuläre Primär- und Sekundärprävention. Sind Sie hier schon auf dem neuesten Stand? Unsere Experten beleuchten, wo und warum das bisherige Procedere geändert werden soll und was in der Praxis sinnvoll ist. Holen Sie sich Ihr Update und 2 CME-Punkte beim MMW-Webinar am 24. April von 17.30 bis 19 Uhr. 
Erweiterte Suche
Anmelden
nach oben
Current Rheumatology Reports
Erschienen in: Current Rheumatology Reports 11/2019

01.11.2019 | Infection and Arthritis (K Winthrop, Section Editor)

Chlamydia-Induced Reactive Arthritis: Disappearing Entity or Lack of Research?

verfasst von: Henning Zeidler, Alan P. Hudson

Erschienen in: Current Rheumatology Reports | Ausgabe 11/2019

Einloggen, um Zugang zu erhalten

Abstract

Purpose of Review

Recent studies regarding the frequency of Chlamydia-induced reactive arthritis (ReA) are reviewed, with a focus on the question of whether the entity is in fact disappearing or whether it is simply being underdiagnosed/underreported. Epidemiological reports indicate diversity in the frequency of Chlamydia-associated ReA in various parts of the world, with evidence of declining incidence in some regions.

Recent Findings

The hypothesis that early effective treatment with antibiotics prevents the manifestation of Chlamydia-associated ReA requires further investigation.

Summary

For clinicians, it is important to remember that ReA secondary to Lymphogranuloma venereum (LGV) serovars L1–L3 of C. trachomatis is probably underestimated due to a limited awareness of this condition, the re-emergence in Western countries of LGV overall, and the present increasingly rare classical inguinal presentation.
Literatur
1.
•• Carter, JD HAP. Recent advances and future directions in understanding and treating Chlamydia-induced reactive arthritis. Expert Rev Clin Immunol. 2017;13:197–206. The review highlights several basic science and clinical aspects of reactive arthritis that are central to our current understanding of the disease. The authors provide suggestions for future research which will provide significant bases for more detailed understanding of, and therefore cure of, the disease.CrossRef
2.
•• Zeidler H, Hudson AP. Causality of chlamydiae in arthritis and spondyloarthritis: a plea for increased translational research. Curr Reumatol Rep. 2016;18:9. The review focuses on lacunae in our understanding of the causation of reactive arthritis and spondyloarthritis, ending with a plea for more study leading to better treatments.CrossRef
3.
Denison HJ, Curtis EM, Clynes MA, Bromhead C, Dennison EM, Grainger R. The incidence of sexually acquired reactive arthritis: a systematic literature review. Clin Rheumatol. 2016;35:2639–48.CrossRef
4.
Essenmacher AC, Khurram N, Bismack GT. A case of reactive arthritis due to Clostridium difficile colitis. J Community Hosp Intern Med Perspect. 2016;6:30151.CrossRef
5.
Schmitt SK. Reactive arthritis. Infect Dis Clin N Am. 2017;31:265–77.CrossRef
6.
Taylor-Robinson D, Keat A. Observations on Chlamydia trachomatis and other microbes in reactive arthritis. Int J STD AIDS. 2015;26:139–44.CrossRef
7.
Iliopoulos A, Karras D, Ioakimidis D, Arvanitis A, Tsamis N, Iakovou I, et al. Change in the epidemiology of Reiter’s syndrome (reactive arthritis) in the post-AIDS era? An analysis of cases appearing in the Greek Army. J Rheumatol. 1995;22:252–4.
8.
Witkin SS, Minis E, Athanasiou A, et al. Chlamydia trachomatis: the persistent pathogen. Clin Vaccine Immunol. 2017;5:24.
9.
O'Connell CM, Ferone ME. Chlamydia trachomatis genital infections. Microb Cell. 2016;3:390–403.CrossRef
10.
Lausen M, Christiansen G, Bouet Guldbæk Poulsen T, Birkelund S. Immunobiology of monocytes and macrophages during Chlamydia trachomatis infection. Microbes Infect. 2018. pii: S1286-4579(18)30192-8.
11.
•• Panzetta, ME VRH, Saka HA. Chlamydia Persistence: A survival strategy to evade antimicrobial effects in-vitro and in-vivo. Front Microbiol. 2018;9:3101. This thorough and well-written review focuses on genetic and metabolic strategies employed by the human chlamydial pathogens to avoid the stress and deleterious effects of antibiotic and other treatments.CrossRef
12.
Cossé MM, Barta ML, Fisher DJ, Oesterlin LK, Niragire B, Perrinet S, et al. The loss of expression of a single Type 3 Effector (CT622) strongly reduces Chlamydia trachomatis infectivity and growth. Front Cell Infect Microbiol. 2018;8:145.
13.
Shaw JH, Key CE, Snider TA, Sah P, Shaw EI, Fisher DJ, et al. Genetic inactivation of Chlamydia trachomatis inclusion membrane protein CT228 alters MYPT1 recruitment, extrusion production, and longevity of infection. Front Cell Infect Microbiol. 2018;8:415.
14.
15.
• Pokorzynski ND, Thompson CC, Carabeo RA. Ironing out the unconventional mechanisms of iron acquisition and gene regulation in Chlamydia. Front Cell Infect Microbiol. 2017;7:394. This interesting review focuses on what we do and as yet do not understand regarding the critical issue of iron acquisition by chlamydiae.CrossRef
16.
Al-Zeer MA, Xavier A, Abu Lubad M, et al. Chlamydia trachomatis prevents apoptosis via activation of PDPK1-MYC and enhanced mitochondrial binding of hexokinase II. EBioMedicine. 2017;23:100–10. doi: 0.1016.CrossRef
17.
Pruneda JN, Bastidas RJ, Bertsoulaki E, Swatek KN, Santhanam B, Clague MJ, et al. A Chlamydia effector combining deubiquitination and acetylation activities induces Golgi fragmentation. Nat Microbiol. 2018;3:1377–84.CrossRef
18.
• Sixt BS, Valdivia RH. Molecular genetic analysis of Chlamydia Species. Annu Rev Microbiol. 2016;70:179–98. An interesting and important review focused on genetic aspects of chlamydiae and how they may influence pathogenesis.CrossRef
19.
Carter JD, Hudson AP. Reactive arthritis: clinical aspects and medical management. Rheum Dis Clin N Am. 2009;35:21–34.CrossRef
20.
21.
c.f. references Mason E, Wray L, Foster R, Jamil MS, Guy R, McNulty A, Donovan B. Reactive arthritis at the Sydney Sexual Health Centre 1992–2012: declining despite increasing chlamydia diagnoses. Int J STD AIDS. 2016;27:882–889.CrossRef
22.
•• Denison HJ, Curtis EM, Clynes MA, et al. The incidence of sexually acquired reactive arthritis: a systematic literature review. Clin Rheumatol. 2016;35:2639–48. First systematic literature review to collate and critically evaluate the published evidence regarding the incidence of SARA. After screening, 55 papers were assessed in full, from which 3 met the relevant inclusion criteria for the review. The studies reported an incidence of SARA of 3.0% - 8.1% and were found to be of low to moderate quality. A suggested screening tool, adapted for use in future studies of the incidence of SARA is included.CrossRef
23.
Keat AC, Maini RN, Nkwazi GC, et al. Role of Chlamydia trachomatis and HLA-B27 in sexually acquired reactive arthritis. Brit Med J. 1978;1:605–7.CrossRef
24.
Rich E, Hook IEW, Alarcon GS, Moreland LW. Reactive arthritis in patients attending an urban sexually transmitted diseases clinic. Arthritis Rheum. 1996;39:1172–7.CrossRef
25.
Carter JD, Rehman A, Guthrie JP, et al. Attack rate of Chlamydia-induced reactive arthritis and effect of the CCR5-Delta-32 mutation: a prospective analysis. J Rheumatol. 2013;40:1578–82.CrossRef
26.
Kvien TK, Glennås A, Melby K, et al. Reactive arthritis: incidence, triggering agents, and clinical presentation. J Rheumatol. 1994;21:115–22.PubMed
27.
Söderlin MK, Kautiainen H, Puolakkainen M, et al. Infections preceding early arthritis in southern Sweden: a prospective population-based study. J Rheumatol. 2003;30:459–64.PubMed
28.
•• Mason E, Wray L, Foster R, et al. Reactive arthritis at the Sydney Sexual Health Centre 1992–2012: declining despite increasing Chlamydia diagnoses. Int J STD AIDS. 2016;27:882–9. The first retrospective case-control study of reactive arthritis in a primary care setting in Australia found a decline in reactive arthritis diagnoses despite an increase in Chlamydia diagnoses. This study allows exploration of trends and risk factors in milder presentations of ReA, rather than the more severe presentations seen in specialist rheumatology practice. The reason for this apparent disconnect between Chlamydia and its complications is unknown. The strength of the study was the long time period of analysis; however, the small sample size, the retrospective study design and missing urine and/or blood and synovial PCR testing for Chlamydia are limitations.
29.
• Ostaszewska-Puchalska I, Zdrodowska-Stefanow B, Kuryliszyn-Moskal A, et al. Incidence of Chlamydia trachomatis infection in patients with reactive arthritis. Reumatologia. 2015;53:69–73. The study reports the rate of C.tr. infection in the urethral and cervical smears of patients with reactive arthritis in a defined area in Poland compared with a control group of volunteers without urogenital or joint symptoms. No correlations between detecting the presence of C.tr. in the urogenital tract and the presence of specific IgA class antibodies in the serum of reactive arthritis patients were observed.
30.
•• Okamoto H. Prevalence of Chlamydia-associated reactive arthritis. Scan J Rheumatol. 2017;46:415–6. The prospective study from 2009 to 2016 assessed the prevalence of Chlamydia-associated reactive arthritis among patients with proved C.tr. genital infection attending an urban clinic of general practice and rheumatology in Tokyo. Only one patient out of the 123 patients enrolled in this study has developed ReA indicating a lower prevalence of Chlamydia-associated ReA than reported previously.
31.
•• Brinster A, Guillot X, Prati C. Wendling D. Evolution over thirty years of the profile of inpatients with reactive arthritis in a tertiary rheumatology unit. Rheumatol Clin. 2018;14:36–9. The retrospective monocentric study did not find a decline in the frequency of C.tr. ReA in inpatients in one French rheumatological department.CrossRef
32.
Hannu T, Puolakkainen M, Leirisalo-Repo M. Chlamydia pneumoniae as a triggering infection in reactive arthritis. Rheumatology (Oxford). 1999;38:411–4.CrossRef
33.
Carter JD, Gérard HC, Espinoza LR, et al. Chlamydiae as etiologic agents in chronic undifferentiated spondylarthritis. Arthritis Rheum. 2009;60:1311–6.CrossRef
34.
Burillo A, Bouza E. Chlamydophila pneumoniae. Infect Dis Clin North Am. 2010;24:61–71.CrossRef
35.
• Sachse K, Rahman KS, Schnee C, et al. A novel synthetic peptide microarray assay detects Chlamydia species-specific antibodies in animal and human sera. Sci Rep. 2018;8:4701. A novel microarray was designed carrying 52 synthetic peptides representing B-cell epitopes from immunodominant proteins of all 11 chlamydial species. In samples from humans, dual infection with C.tr. and C.pn. could be demonstrated.
36.
Gaydos CA, Quinn TC, Willis D, et al. Performance of the APTIMA Combo 2 Assay for detection of Chlamydia trachomatis and Neisseria gonorrhoeae in female urine and endocervical swab specimens. J Clin Microbiol. 2003;41:304–9.CrossRef
37.
• Foschi C, Banzola N, Gaspari V, et al. A case of reactive arthritis associated with Lymphogranuloma venereum infection in a woman. Sex Transm Dis. 2016;43:584–6. First case of reactive arthritis associated with LGV in a human immunodeficiency virus – negative woman with urogenital and rectal C. tr. L2 serovar infection.CrossRef
38.
Desclaux A, Mehsen-Cetre N, Peuchant O, et al. Reactive arthritis associated with Chlamydia trachomatis genovar L2b proctitis. Med Mal Infect. 2017;47:177–8.CrossRef
39.
Stoner BP, Cohen SE. Lymphogranuloma venereum 2015: Clinical presentation, diagnosis, and treatment. Clin Infect Dis. 2015;61(Suppl 8):S865–73.CrossRef
40.
Dal Conte I, Mistrangelo M, Cariti C, et al. Lymphogranuloma venereum: an old, forgotten re-emerging systemic disease. Panminerva Med. 2014;56:73–83.PubMed
41.
Sawada T, Suehiro M, Takaya K. Lower-leg cellulitis-like manifestations of erythema nodosum induced by Chlamydophila pneumoniae infection. Indian J Dermatol. 2016;61:237.CrossRef
42.
•• Zeidler H, Hudson A. Coinfection of chlamydiae and other bacteria in reactive arthritis and spondyloarthritis: need for future research. Microorganisms. 2016;4:30. The review reports coinfections involving chlamydiae, M. hominis, and U. urealyticum in patients with post-venereal ReA, indicating a clear and critical unmet need for future research to understand the nature and consequences of coinfections for diagnostics, clinical course, and treatment of chlamydial arthritis and SpA.
43.
Wolford LM. Understanding TMJ reactive arthritis. Cranio. 2017;35:274–5.CrossRef
44.
Henry CH, Hughes CV, Gérard HC, et al. Reactive arthritis: preliminary microbiologic analysis of the human temporomandibular joint. J Oral Maxillofac Surg. 2000;58:1137–42.CrossRef
45.
Edvinsson M, Welvaart N, Ryttberg L, et al. No evidence of Chlamydia pneumoniae in the synovia of patients with osteoarthritis. J Int Med Res. 2019;47:635–40.CrossRef
46.
47.
•• Carter JD, Hudson AP. Recent advances and future directions in understanding and treating Chlamydia-induced reactive arthritis. Expert Rev. Clin Immunol. 2017;13:197–206. The most recent and comprehensive article reviewing approaches to treatment of Chlamydia-induced reactive arthritis in the context of clinical aspects and the biology of the chlamydiae as it relates to elicitation of the disease.CrossRef
48.
Zigangirova NA, Morgunova EY, Fedina ED, et al. Lycopene inhibits propagation of Chlamydia infection. Scientifica (Cairo). 2017;2017:1478625.
Metadaten
Titel
Chlamydia-Induced Reactive Arthritis: Disappearing Entity or Lack of Research?
verfasst von
Henning Zeidler
Alan P. Hudson
Publikationsdatum
01.11.2019
Verlag
Springer US
Erschienen in
Current Rheumatology Reports / Ausgabe 11/2019
Print ISSN: 1523-3774
Elektronische ISSN: 1534-6307
DOI
https://doi.org/10.1007/s11926-019-0863-4

Weitere Artikel der Ausgabe 11/2019

Current Rheumatology Reports 11/2019 Zur Ausgabe

Inflammatory Muscle Disease (I Lundberg and L Diederichsen, Section Editors)

PET Scan: Nuclear Medicine Imaging in Myositis

Vasculitis (L Espinoza, Section Editor)

Understanding the Cryoglobulinemias

Complementary and Alternative Medicine (S Kolasinski, Section Editor)

Qigong and Musculoskeletal Pain

Spondyloarthritis (M Khan, Section Editor)

“Mobile Health” for the Management of Spondyloarthritis and Its Application in China

Inflammatory Muscle Disease (I Lundverg and L Diederichsen, Section Editors)

Patient-Reported Outcomes in Adult Idiopathic Inflammatory Myopathies

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

19.04.2024 | Vorhofflimmern | Nachrichten

Parodontalbehandlung verbessert Prognose bei Katheterablation

19.04.2024 | EAU 2024 | Kongressbericht | Nachrichten

Prostatakarzinom: EU initiiert neues Screeningkonzept

19.04.2024 | EAU 2024 | Kongressbericht | Nachrichten

Blasenkarzinom – Biomarker statt Zytologie?

18.04.2024 | Arterielle Hypertonie | Nachrichten

Antihypertensiva schützen auch alte Menschen noch vor Demenz
weitere anzeigen

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen
Bildnachweise